Pliant Therapeutics, Inc. Common Stock
PLRX
PLRX: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
moreShow PLRX Financials
Recent trades of PLRX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by PLRX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: N-acyl amino acid compounds and methods of use Jun. 13, 2023
-
Patent Title: Amino acid compounds and methods of use Apr. 25, 2023
-
Patent Title: Amino acid compounds and methods of use Jan. 24, 2023
-
Patent Title: Dosage forms and regimens for amino acid compounds Aug. 23, 2022
-
Patent Title: Amino acid compounds with unbranched linkers and methods of use Jul. 26, 2022
-
Patent Title: Substituted amino acids as integrin inhibitors Nov. 23, 2021
-
Patent Title: Amino acid compounds and methods of use Oct. 06, 2020
-
Patent Title: Amino acid compounds and methods of use Jun. 30, 2020
Federal grants, loans, and purchases
Followers on PLRX's company Twitter account
Number of mentions of PLRX in WallStreetBets Daily Discussion
Recent insights relating to PLRX
Recent picks made for PLRX stock on CNBC
ETFs with the largest estimated holdings in PLRX
Flights by private jets registered to PLRX